How Much Is Wegovy: Understanding Costs and Clinical Personalization Options

Last reviewed: May 27, 2026

Last updated: May 27, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Wegovy (injectable semaglutide) typically costs between $200 and $600 per month without insurance, making affordability a major consideration for patients exploring weight management. Most out-of-pocket patients use manufacturer savings programs or opt for compounded alternatives to reduce cost burden.

Understanding Wegovy's pricing structure matters not just for budgeting, but because cost-effectiveness discussions often overlook an important clinical component: individual genetic variation in GLP-1 receptor pathways. PlexusDx focuses on precision wellness by helping patients understand whether their biology may align with particular treatment options and pricing tiers.

Wegovy Pricing Tiers and Monthly Cost Breakdown

Wegovy comes in four injectable doses: 0.25 mg, 0.5 mg, 1 mg, and 2.4 mg. Patients typically begin at 0.25 mg and escalate every four weeks. Full dose escalation takes approximately 16–20 weeks, during which monthly costs remain consistent regardless of dose.

List prices range from roughly $200/month for low-dose pens to $550–$600/month at the 2.4 mg maintenance dose. Novo Nordisk's GoodRx coupon programs may reduce costs to $150–$250/month for uninsured patients, though availability varies by state and pharmacy.

Insurance Coverage, Out-of-Pocket Maximums, and Real-World Cost Scenarios

Insurance coverage for Wegovy has expanded but remains variable. Medicare does not cover it; most commercial plans require prior authorization and may impose restrictions based on BMI, comorbidities, or prior medication trials. Copay or coinsurance ranges from $0–$300 per month for covered patients.

Coverage Scenario	Typical Monthly Cost	Annual Estimate	Key Factors
No insurance + manufacturer coupon	$150–$250	$1,800–$3,000	GoodRx availability, state regulations
Commercial insurance with copay	$0–$100	$0–$1,200	Plan formulary status, prior auth approval
Commercial insurance with 20% coinsurance	$40–$120	$480–$1,440	Deductible met; typical tier 2 specialty drug
No coverage, full price out-of-pocket	$500–$600	$6,000–$7,200	No subsidies or assistance programs

Genetic Predispositions in GLP-1 Signaling and Cost-Effectiveness Context

Individual variation in GLP-1 receptor genes (such as GLP1R rs6923761) may influence responsiveness to GLP-1 medications. While genetic testing does not predict exact dosing or cost, understanding whether a patient carries predispositions associated with higher or lower GLP-1 signaling capacity can support more informed conversations about treatment selection and expected timeline.

PlexusDx's Precision Peptide Genetic Test reveals variants in GLP1R, GIPR, FTO, and MC4R pathways. This context may help patients and providers discuss whether branded Wegovy, compounded semaglutide, dual-compound formulations, or microdose protocols align best with both clinical expectations and budget constraints.

Compounded Alternatives and How They Compare on Cost and Personalization

Compounded semaglutide (licensed 503A pharmacies) typically ranges from $149 monthly, undercutting branded Wegovy list prices. Compounded tirzepatide costs $249/mo. These alternatives offer transparent pricing without insurance requirements, appealing to uninsured or underinsured patients seeking cost predictability.

Importantly, compounded medications are not FDA-approved branded products and require prescriber oversight. Their potential advantage lies in lower cost, flexible dosing, and the ability to pair genetic insights (via the Precision Peptide test) with personalized formulation discussions. A qualified healthcare provider should guide this decision alongside your clinical history and goals.

Safety Considerations and Who Should Evaluate Cost-Effectiveness With a Provider

Cost should never be the sole driver of treatment selection. GLP-1 medications carry contraindications (personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2) and common side effects (nausea, vomiting, pancreatitis risk). A qualified provider must review your complete medical history before recommending any option.

Patients with diabetes, cardiovascular disease, or complex medication regimens especially need individualized cost-benefit analysis. Genetic testing can support this conversation by providing context on peptide pathway predispositions, but should always be interpreted within a comprehensive clinical evaluation, not as a standalone decision tool.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test can provide context on your individual predispositions in GLP-1, GIPR, FTO, and MC4R pathways. Variants like GLP1R rs6923761 may help inform discussions about responsiveness patterns, though genetic data alone does not predict exact medication response or dosing needs.

The test costs $99 as an add-on with a treatment order or $298 standalone. Revealing your genetic predispositions in peptide signaling pathways may help you and your provider have a more informed conversation about whether branded Wegovy, compounded semaglutide, tirzepatide, or other options align with your biology and budget.

Understanding genetic context alongside cost and insurance coverage can support more personalized treatment planning. PlexusDx's transparent pricing on compounded alternatives ($149/mo) combined with genetic insights may help you explore cost-effective options that still align with your individual clinical profile.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Does insurance typically cover Wegovy?

Coverage varies by plan and often requires prior authorization. Medicare does not cover it. Commercial plans may require BMI thresholds or medication trial history. Copays typically range $0–$300/month for covered patients.

What is the actual monthly cost of Wegovy without insurance?

List price is $200–$600/month depending on dose. Manufacturer coupons (GoodRx) may reduce this to $150–$250/month. Compounded semaglutide alternatives cost $149/mo.

How can genetic testing help me decide between Wegovy and compounded alternatives?

PlexusDx's Precision Peptide Genetic Test reveals predispositions in GLP1R, GIPR, FTO, and MC4R pathways. This context may support your provider discussion about expected responsiveness patterns, helping align treatment selection with both your biology and cost considerations.

Are there safety concerns I should discuss with my provider before choosing based on cost alone?

Yes. GLP-1 medications have contraindications (medullary thyroid carcinoma history, MEN2) and side effects (nausea, pancreatitis risk). Cost should never override medical safety screening. Your provider must review your complete history before recommending any option.

What is the Precision Peptide Genetic Test and what does it reveal?

This $99–$298 test identifies predispositions in GLP-1 receptor, GIPR, FTO, and MC4R genetic variants. It may help provide context for personalized treatment conversations but does not predict exact medication response. A qualified provider should interpret all results.